USFDA classifies inspection at Torrent Pharma’s Indrad facility as OAI

13 Aug 2019

Torrent Pharmaceuticals has received a communication from the US Food & Drug Administration (USFDA) classifying the inspection conducted at its Indrad facility in April, 2019 as Official Action Initiated (OAI).

The Company already had submitted its initial response to USFDA and commitments given in response to Form 483 observations have been fulfilled. The Company is sending further updates over receiving of this OAI letter.

Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Related Torrent Pharmaceuticals Ltd. Links:

Torrent Pharma Share Price

2576.75 -28.00 (-1.07%) Apr 22, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 640.25
Dr. Reddys Lab 5199.70
Lupin 1061.30
Piramal Enterprises 1657.30
Cadila Healthcare 552.25
View more..
Sensex vs Torrent Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback